CA Patent

CA2897302C — Sustained release formulations of lorazepam

Assigned to EDGEMONT PHARMACEUTICALS LLC · Expires 2022-05-31 · 4y expired

What this patent protects

A pharmaceutical composition for delivering lorazepam in a prolonged fashion is achieved with prolonged release lorazepam pharmaceutical beads. The composition typically contains sustained release lorazepam beads and delayed sustained release lorazepam beads. The composition can …

USPTO Abstract

A pharmaceutical composition for delivering lorazepam in a prolonged fashion is achieved with prolonged release lorazepam pharmaceutical beads. The composition typically contains sustained release lorazepam beads and delayed sustained release lorazepam beads. The composition can provide once daily dosing that maintains 24 hour therapeutic effect under steady state conditions.

Drugs covered by this patent

Patent Metadata

Patent number
CA2897302C
Jurisdiction
CA
Classification
—
Expires
2022-05-31
Drug substance claim
No
Drug product claim
No
Assignee
EDGEMONT PHARMACEUTICALS LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.